

Nivolumab for previously treated advanced renal cell carcinoma

Information for the public

Published: 23 November 2016

www.nice.org.uk

What has NICE said?

Nivolumab (Opdivo) is recommended as a possible treatment for adults with previously treated advanced renal cell carcinoma.

What does this mean for me?

If you have advanced renal cell carcinoma, and your doctor thinks that nivolumab is the right treatment, you should be able to have it on the NHS.

The condition and the treatment

Renal cell carcinoma is a kidney cancer that starts in the cells lining the small tubes that help to make urine. In advanced disease, the cancer has spread inside the kidney, and may have spread outside the kidney.

Nivolumab is a drug that helps the body's immune system to recognize and destroy cancer cells. It is given by injection.

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Kidney Cancer UK](#), 0800 002 9002
- [Kidney Research UK](#), 0300 303 1100
- [National Kidney Federation](#), 0845 601 0209
- [British Kidney Patient Association](#), 0142 054 1424
- [Kidney Cancer Support Network](#), 01209 890326

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2167-6

Accreditation

